{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-028690","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.969447+00:00","generated_at":"2026-06-18T11:23:33.004761+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Esperion's CLEAR Outcomes trial shows NEXLETOL reduces CV risk 13-23% in statin-intolerant patients","bullets":["NEXLETOL reduced MACE-4 by 13% (p=0.004), MACE-3 by 15% (p=0.006), heart attack by 23% (p=0.002), and coronary revascularization by 19% (p=0.001) vs placebo.","First LDL-C lowering therapy since statins to reduce hard ischemic events in both primary and secondary prevention patients.","Regulatory filings to FDA and EMA expected in 1H 2023; potential partner milestone payments up to $440M ($300M EU label, $140M other milestones).","Full-year 2023 operating expenses guided at $225M-$245M, including $25M non-cash stock compensation.","Results published in NEJM and presented at ACC.23/WCC; conference call scheduled for March 6, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-028690","json":"https://secwatch.observer/filing/0001104659-23-028690.json","markdown":"https://secwatch.observer/filing/0001104659-23-028690.md","text":"https://secwatch.observer/filing/0001104659-23-028690.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000110465923028690/0001104659-23-028690-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000110465923028690/tm238559d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:23:33.004761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}